Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) saw a significant growth in short interest in October. As of October 31st, there was short interest totalling 78,900 shares, a growth of 54.1% from the October 15th total of 51,200 shares. Approximately 1.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 123,300 shares, the short-interest ratio is presently 0.6 days.

Hedge Funds Weigh In On Adial Pharmaceuticals

A hedge fund recently bought a new stake in Adial Pharmaceuticals stock. Virtu Financial LLC bought a new position in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 20,469 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned approximately 0.48% of Adial Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 16.41% of the stock is currently owned by institutional investors and hedge funds.

Adial Pharmaceuticals Price Performance

NASDAQ:ADIL opened at $0.99 on Thursday. The stock has a fifty day moving average of $1.02 and a 200 day moving average of $1.14. Adial Pharmaceuticals has a 52-week low of $0.77 and a 52-week high of $4.17.

Adial Pharmaceuticals (NASDAQ:ADIL) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.20). Equities analysts predict that Adial Pharmaceuticals will post -1.79 earnings per share for the current fiscal year.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.